Table 4.
PCSK9 levels in relation to MACEs in patients with different diabetic status
| PCSK9 (ng/mL) | HR (95% CI) | ||
|---|---|---|---|
| Crude model | Model 1 | Model 2 | |
| Non-DM | |||
| PCSK9 per-SD increase | 1.543 (1.224–1.945)b | 1.571 (1.232–2.004)b | 1.458 (1.128–1.885)b |
| PCSK9 < 234.52 ng/mL | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| PCSK9 ≥ 234.52 ng/mL | 2.137 (1.210–3.775)b | 2.140 (1.206–3.795)b | 2.100 (1.174–3.757)a |
| DM | |||
| PCSK9 per-SD increase | 1.258 (0.975–1.623) | 1.262 (0.972–1.639) | 1.361 (1.037–1.785)a |
| PCSK9 < 234.52 ng/mL | 2.430 (1.264–4.467)b | 2.424 (1.260–4.663)b | 3.033 (1.442–6.376)b |
| PCSK9 ≥ 234.52 ng/mL | 4.092 (2.297–7.290)b | 4.084 (2.274–7.333)b | 5.233 (2.546–10.757)b |
MACEs major adverse cardiovascular events, non-DM diabetes mellitus, non-DM non-diabetes mellitus, CI confidence interval, HR hazard ratio, Model 1 adjusted for age and sex; Model 2 adjusted for model 1, body mass index, smoking, drinking, hypertension, family history of coronary artery disease, Gensini score, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride, fasting plasma glucose, hemoglobin A1c, fibrinogen and β-blockers
afor p < 0.05
bfor p < 0.01